The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...

Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy ...

That was among the many special moments for 11-year-old Cooper Trueblood at the Washington Capitals’ annual Hockey Fights ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

When Lightning coach Jon Cooper thinks about the legacy he wants to leave in Tampa Bay, winning games and hoisting the Stanley Cup is certainly part of it. But when you hear him grab a microphone and ...

A mother who claims her GP said her four-year-old daughter was “faking it” a week before she was diagnosed with blood cancer ...

The therapy was cleared to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) after showing complete remission in 63% of efficacy evaluable patients during Autolus’ ...

Prior to this, Summer, from Hampshire, had been "constantly poorly" and bruising easily. However, when Rebecca, 33, took her ...

Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...